Xilio Therapeutics, Inc.
NASDAQ:XLOBiotechnology
+$0.45 today
- Market cap
- $53.90M
- Beta
- -0.09
- P/E (TTM)
- -48.1
- EPS (TTM)
- -$0.19
Volume 0.01M
Average 0.05M
XLO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Xilio Therapeutics, Inc.NASDAQ: XLO
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $344K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $15.67M.
Context
- Cost of revenue amounted to 3.5% of revenue in FY2025, up 3.5 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $344K or moves back toward the trailing-twelve-month quarterly average of $3.92M.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.54M USD
- Year-over-year change
- —
- 4-year CAGR
- +0.7%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.54M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 1.5M | — |
Cost of Revenue vs competitors
How XLO compares with its peers on the latest reported figures
- XLO's LTM Mar 2026 cost of revenue of $15.67M is the highest of the 4 companies compared; the peer median is $0.
- Cost of revenue amounts to 29.3% of revenue for XLO, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.67M | — | — | 29.3% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $203K | +1591.7% | — | — |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Jun 2026 | -$395K | -197.3% | — | 1.1% | |
| Peer median (excluding XLO) | $0 | -100.0% | — | 1.1% | |
Competitors are the stored peer set for XLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 6.34M | 43.77M |
| Cost of Revenue | 1.5M | 0 | 0 | 0 | 1.54M |
| Gross Profit | (1.5M) | 0 | 0 | 6.34M | 42.23M |
| Gross Margin | — | — | — | 100.0% | 96.5% |
| Research & Development | 51.19M | 59.2M | 52.14M | 41.21M | 56.04M |
| Selling, General & Admin | 22.36M | 29.95M | 27M | 24.78M | 29.71M |
| Operating Expenses | 73.55M | 89.15M | 79.13M | 66.93M | 84.21M |
| Depreciation & Amortization | 1.5M | 1.85M | 1.9M | 1.64M | 1.54M |
| EBITDA | (73.7M) | (86.38M) | (74.5M) | (58M) | (33.5M) |
| EBITDA Margin | — | — | — | -914.3% | -76.5% |
| Operating Income | (75.04M) | (89.15M) | (79.13M) | (60.58M) | (41.98M) |
| Operating Margin | — | — | — | -954.9% | -95.9% |
| Interest Income | 600 | 0 | 0 | 0 | 3.4M |
| Interest Expense | 600K | 0 | 0 | 100K | 0 |
| Other Income / Expenses | (756K) | 927K | 2.73M | 2.34M | 6.95M |
| Income Before Tax | (75.8M) | (88.22M) | (76.4M) | (58.24M) | (35.04M) |
| Pre-Tax Margin | — | — | — | -918.0% | -80.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (75.8M) | (88.22M) | (76.4M) | (58.24M) | (35.04M) |
| Net Margin | — | — | — | -918.0% | -80.1% |
| EPS (Basic) | (189.28) | (45.08) | (38.92) | (15.26) | (4.19) |
| EPS (Diluted) | (189.28) | (45.08) | (38.92) | (15.26) | (4.19) |
| Weighted Avg Shares | 400.45K | 1.96M | 1.96M | 3.82M | 83.59M |
| Weighted Avg Shares (Diluted) | 400.45K | 1.96M | 1.96M | 3.82M | 83.59M |
Xilio Therapeutics, Inc.
NASDAQ:XLO
Intrinsic Alpha fair value
Locked
Current Price
$7.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.